{
    "clinical_study": {
        "@rank": "154626", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1-SD: Belatacept + Tacrolimus + CsA", 
                "arm_group_type": "Experimental", 
                "description": "Belatacept 7.5-12.5 mg/kg intravenous (IV) infusion once in 2 months\nTacrolimus capsule by mouth as per label for 2 months\nCyclosporine (CsA) capsule or liquid by mouth as per label for 2 months"
            }, 
            {
                "arm_group_label": "Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA", 
                "arm_group_type": "Experimental", 
                "description": "Belatacept 7.5-12.5 mg/kg intravenous (IV) infusion every 2 weeks until week 8 then every 4 weeks for 3 years\nTacrolimus capsule by mouth as per label for 3 years\nOR\nCyclosporine (CsA) capsule or liquid by mouth as per label for 3 years"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the pharmacokinetics (PK) efficacy and safety of\n      Belatacept in stable pediatric renal transplant recipients."
        }, 
        "brief_title": "Phase II Pharmacokinetics, Efficacy, and Safety of Belatacept in Pediatric Renal Transplant Recipients", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Transplant", 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  6-17 years old\n\n          -  Recipients of a renal allograft from a living donor or a deceased donor at least 6\n             months prior to enrollment\n\n          -  Subject must be receiving a calcineurin inhibitor (CNI)-based [cyclosporine (CsA)\n             [any formulation] or Tacrolimus (TAC)] immunosuppressive regimen\n\n          -  Subject must be receiving adjunctive background maintenance immunosuppression with\n             mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium\n             (EC-MPS)/mycophenolic acid (MPA)\n\n          -  Subjects must be receiving a stable dose of corticosteroids\n\n          -  Subject must have stable estimated glomerular filtration rate (GFR) \u226545 mL/min/1.73m2\n             (updated Schwartz formula)\n\n        Exclusion Criteria:\n\n          -  Epstein-Barr virus (EBV) serostatus negative or unknown at time of transplant and\n             screening\n\n          -  History of any treated or biopsy proven acute rejection (BPAR) within 3 months prior\n             to randomization\n\n          -  Subjects who have experienced more than 1 episode of acute rejection (AR) of the\n             current allograft or any antibody-mediated AR\n\n          -  Significant proteinuria\n\n          -  Active infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791491", 
            "org_study_id": "IM103-144", 
            "secondary_id": "2011-005257-31"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1-SD: Belatacept + Tacrolimus + CsA", 
                    "Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA"
                ], 
                "intervention_name": "Belatacept", 
                "intervention_type": "Drug", 
                "other_name": "BMS-224818"
            }, 
            {
                "arm_group_label": [
                    "Arm 1-SD: Belatacept + Tacrolimus + CsA", 
                    "Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA"
                ], 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Prograf"
            }, 
            {
                "arm_group_label": [
                    "Arm 1-SD: Belatacept + Tacrolimus + CsA", 
                    "Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA"
                ], 
                "intervention_name": "CsA", 
                "intervention_type": "Drug", 
                "other_name": "Neoral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tacrolimus", 
                "Abatacept"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Daniel Feig, Site 0004", 
                    "phone": "205-638-2792"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "University Of Alabama At Birmingham"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kevin Lemley, Site 0001", 
                    "phone": "323-361-7299"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Childrens Hospital Of La"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robert Ettenger, Site 0002", 
                    "phone": "310-206-8415"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University Of California Los Angeles"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Grimm, Site 0006", 
                    "phone": "650-725-5295"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Asha Moudgil, Site 0007", 
                    "phone": "202-476-2245"
                }, 
                "facility": {
                    "address": {
                        "city": "District of Columbia", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Childrens National Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Barry Warshaw, Site 0012", 
                    "phone": "404-712-9923"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Harmon, Site 0008", 
                    "phone": "617-355-8314"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Boston Childrens Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vikas Dharnidharka, Site 0003", 
                    "phone": "314-747-1349"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sandra Amaral, Site 0009", 
                    "phone": "267-425-3932"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children'S Hospital Of Philadelphia"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Austria: Agency for Health and Food Safety", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Time of maximum observed serum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Half-life (T-HALF)", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Total body clearance (CLT)", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Volume of distribution at steady-state (Vss)", 
                "safety_issue": "No", 
                "time_frame": "8 time points following SD administration up to Day 57"
            }, 
            {
                "measure": "Steady state trough concentration (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "25 time points following MD administration up to Week 24 of Follow-up"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety will be measured by proportion of subjects reporting Adverse Event (AE), Serious AE, and AE leading to early discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "12, 24 and 36 months"
            }, 
            {
                "measure": "Antibody titers against Belatacept", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, 15, 29, and 57 in SD phase; Day 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365, every 6 months up to 3 Years , Weeks  8,12, 24 follow up in MD phase"
            }, 
            {
                "measure": "CD86 receptor occupancy in Blood samples", 
                "safety_issue": "No", 
                "time_frame": "Day1, 29 and 57 in SD phase; Day1, 29, 57, Month 6, and 12 in MD phase"
            }, 
            {
                "measure": "Efficacy as measured by estimated glomerular filtration rate (eGFR) [calculated by updated Schwartz formula]", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 12, 24, and 36 months in MD and Long Term Extension (LTE) phases"
            }, 
            {
                "measure": "Efficacy as measured by change in eGFR", 
                "safety_issue": "No", 
                "time_frame": "Day 1, Month 12, 24 and 36 in MD and LTE phases"
            }, 
            {
                "measure": "Efficacy as measured by incidence and severity of AR", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 24, and 36 months  in MD and LTE phases"
            }, 
            {
                "measure": "Efficacy as measured by incidence of death and graft loss", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 24, and 36 months in MD and LTE phases"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}